Y Intercept Hong Kong Ltd Buys 40,186 Shares of Hims & Hers Health, Inc. $HIMS

Y Intercept Hong Kong Ltd lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 62.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 104,600 shares of the company’s stock after acquiring an additional 40,186 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Hims & Hers Health were worth $5,214,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Bessemer Group Inc. boosted its stake in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after acquiring an additional 312 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Hims & Hers Health by 41.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 83,844 shares of the company’s stock valued at $4,180,000 after purchasing an additional 24,726 shares during the period. Nisa Investment Advisors LLC boosted its stake in Hims & Hers Health by 299.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 18,824 shares of the company’s stock valued at $938,000 after purchasing an additional 14,106 shares during the period. Wealthfront Advisers LLC bought a new stake in Hims & Hers Health during the 2nd quarter valued at approximately $265,000. Finally, State of New Jersey Common Pension Fund D boosted its stake in Hims & Hers Health by 0.8% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 62,163 shares of the company’s stock valued at $3,099,000 after purchasing an additional 507 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Zacks Research cut Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 19th. KeyCorp began coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Wall Street Zen cut Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Finally, Truist Financial dropped their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $38.92.

Insiders Place Their Bets

In related news, insider Patrick Harrison Carroll sold 10,021 shares of the stock in a transaction that occurred on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $506,060.50. Following the sale, the insider directly owned 169,940 shares in the company, valued at $8,581,970. This represents a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,592 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $57.13, for a total value of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares in the company, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,429,634 shares of company stock valued at $74,097,471 in the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Stock Down 0.8%

NYSE HIMS opened at $48.40 on Tuesday. The firm has a market cap of $10.94 billion, a PE ratio of 60.50, a price-to-earnings-growth ratio of 3.38 and a beta of 2.25. Hims & Hers Health, Inc. has a one year low of $18.33 and a one year high of $72.98. The stock’s 50 day simple moving average is $51.20 and its 200 day simple moving average is $49.94. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm’s revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the company earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.